The phase 3 bepirovirsen trial introduces critical clinical considerations for hepatitis B management. First, this antisense oligonucleotide employs a fundamentally different therapeutic mechanism compared to standard care—targeting viral RNA directly to reduce surface antigen production rather than merely suppressing replication. This distinction is clinically significant for patients who have not achieved HBsAg loss on conventional nucleoside analogues.
Second, the global burden remains substantial: approximately 296 million people require improved treatment options, with current therapies offering limited functional cure potential. Third, bepirovirsen’s trial endpoints—sustained HBsAg loss and undetectable HBV DNA—align with WHO-defined functional cure criteria, providing clinically meaningful outcomes beyond viral suppression alone.
These trial results suggest a paradigm shift in hepatitis B therapeutics, offering clinicians a potential new tool for patients seeking cure rather than lifelong suppressive therapy. Understanding this mechanism positions healthcare providers to better counsel patients about emerging treatment alternatives.
Read the full article on GMJ Newsroom.
Was this article helpful?
